FrancophonIA/ELRC3.0 huggingface dataset:
English: Therefore, the combination of valsartan with an ACE inhibitor is not recommended.
Slovenian: Zato uporaba kombinacije valsartana z zaviralcem ACE ni priporočena.
English: The dosing schedule for the therapeutic use of valsartan in heart failure was based on the Val-HeFT study.
Slovenian: Shema odmerjanja za terapevtsko uporabo valsartana pri srčnem popuščanju je temeljila na študiji ValHeFT.
English: Like all medicines, Diovan can cause side effects, although not everybody gets them.
Slovenian: Kot vsa zdravila ima lahko tudi zdravilo Diovan neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
English: What Diovan is and what it is used for Before you take Diovan How to take Diovan Possible side effects How to store Diovan Further information
Slovenian: Kaj je zdravilo Diovan in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Diovan Kako jemati zdravilo Diovan Možni neželeni učinki
English: Baseline therapy included ACE inhibitors (93%), diuretics (86%), digoxin (67%) and beta blockers (36%).
Slovenian: Osnovno zdravljenje je vključevalo zaviralce ACE (93 %), diuretike (86 %), digoksin (67 %) in antagoniste adrenergičnih receptorjev beta (36 %).
English: If you have accidentally taken too many tablets, contact your doctor, pharmacist, or hospital.
Slovenian: Če nehote vzamete preveč tablet, pokličite svojega zdravnika, farmacevta ali v bolnišnico.
English: The CHMP considered the precautions for the concomitant use of other medicinal products containing or raising the level of potassium and adopted the following wording: “If a medicinal product that affects potassium levels is considered necessary in combination with valsartan, monitoring of potassium plasma levels is advised”.
Slovenian: CHMP je preučil previdnostne ukrepe pri sočasni uporabi drugih zdravil, ki vsebujejo ali zvišujejo raven kalija, ter sprejel naslednje besedilo: „Če se uporaba zdravila, ki vpliva na raven kalija, šteje za nujno v kombinaciji z valsartanom, se priporoča spremljanje ravni kalija v plazmi“.
English: The CHMP also considered that in view of the fact that Diovan is eliminated via the biliary route, it should be contraindicated in patients with severe liver diseases and “should not be administered in patients with severe hepatic impairment, cirrhosis or biliary obstruction.
Slovenian: CHMP je poleg tega menil, da mora biti zaradi dejstva, da se zdravilo Diovan izloča po biliarni poti, to zdravilo kontraindicirano pri bolnikih s hudimi boleznimi jeter in „se ga ne sme dajati bolnikom s hudo okvaro jeter, cirozo ali biliarno obstrukcijo“.
English: The potential for hepatic function per se to affect the kinetics of valsartan is therefore limited, except in the case of biliary obstruction or cholestatic liver disease (defined as an alkaline phosphatase concentration > 2 X Upper Limit of Normal).
Slovenian: Iz tega razloga je potencial funkcije jeter kot tak, ki bi lahko vplival na kinetiko valsartana, omejen, razen v primerih biliarne obstrukcije ali holestaze jeter (definirane kot koncentracija alkalne fosfataze > 2-kratnika zgornje meje normalne vrednosti).
English: Valsartan was also effective in prolonging the time to and reducing cardiovascular mortality, hospitalisation for heart failure, recurrent myocardial infarction, resuscitated cardiac arrest, and non-fatal stroke (secondary composite endpoint).
Slovenian: Valsartan je bil učinkovit tudi pri podaljšanju časa do kardiovaskularne smrti in zmanjševanju kardiovaskularne umrljivosti, hospitalizacij zaradi srčnega popuščanja, ponovitev miokardnega infarkta, zastoja srca z uspešnim oživljanjem in možganske kapi, ki ni smrtna (sekundarni sestavljen cilj opazovanja).
English: In Study 27 the kinetic of valsartan was also investigated in hypertensive patients with impairment of renal function (creatine clearance rate: 16-116 mL/min).
Slovenian: V študiji 27 je bila raziskana tudi kinetika valsartana pri hipertenzivnih bolnikih z okvaro delovanja ledvic (kreatininski očistek: 16-116 ml/min).
English: • to treat symptomatic heart failure.
Slovenian: • Za zdravljenje simptomatskega srčnega popuščanja.
English: With reference to the contraindication for the use of Diovan during pregnancy or lactation, the CHMP in line with the recommendations of the Pharmacovigilance experts considered that the contraindication shall be removed and the following recommendation included in the specific section relevant to pregnancy and lactation as follows: “Because no information is available regarding the use of valsartan during breastfeeding, Diovan (Valsartan) is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant”.
Slovenian: V zvezi s kontraindikacijo pri uporabi zdravila Diovan med nosečnostjo in dojenjem je CHMP ob upoštevanju predlogov strokovnjakov za farmakovigilanco menil, da se mora kontraindikacija odstraniti, v posebno poglavje, ki zadeva nosečnost in dojenje, pa se mora vključiti naslednji predlog: „Ker ni razpoložljivih informacij glede uporabe valsartana med dojenjem, zdravilo Diovan (valsartan) ni priporočljivo, primernejša pa so druga nadomestna zdravljenja, ki imajo bolje raziskane profile varnosti med dojenjem, zlasti med dojenjem novorojenca in nedonošenega otroka“.
English: • if you have lost a lot of fluid (dehydration) caused by diarrhoea, vomiting, or high doses of water pills
Slovenian: • če izgubite veliko tekočine (dehidracija) zaradi driske, bruhanja ali velikih odmerkov tablet za odvajanje vode (diuretikov),
English: A number of areas of disharmony in the product information for Diovan have been evaluated by the CHMP and a revised PI was adopted.
Slovenian: CHMP je ovrednotil številna neusklajena področja v informacijah o zdravilu Diovan in sprejel revidirano različico informacij o zdravilu.
English: Based on a pharmacokinetic study, the dose of valsartan should not exceed 80 mg in these patients and should be used with caution.
Slovenian: V skladu z ugotovitvami farmakokinetične študije odmerek valsartana pri teh bolnikih ne sme presegati 80 mg in se ga mora uporabljati previdno.
English: The apparent clearance of valsartan following oral administration is approximately 4.5 l/h.
Slovenian: Navidezni očistek valsartana po peroralni aplikaciji je približno 4,5 l/h.
English: The maximum daily dose administered in clinical trials is 320 mg in divided doses.
Slovenian: Največji odmerek na dan, ki so ga uporabili v kliničnih preskušanjih, je bil 320 mg v razdeljenih odmerkih.
English: Hard capsules
Slovenian: Hard capsules peroralna
English: If not treated it can damage the blood vessels of the brain, heart, and kidneys, and may result in a stroke, heart failure, or kidney failure.
Slovenian: Če ga ne zdravimo, lahko poškoduje krvne žile v možganih, srcu in ledvicah, kar lahko povzroči infarkt, srčno popuščanje ali odpoved ledvic.
English: -Hypersensitivity to the active substance or to any of the excipients.
Slovenian: -Preobčutljivost za zdravilno učinkovino ali katerokoli pomožno snov.
English: The primary benefit was a 27.5% (95% CI: 17 to 37%) reduction in risk for time to first heart failure hospitalisation (13.9% vs. 18.5%).
Slovenian: Primarna korist je bilo 27,5 % (95 % IZ: 17 do 37 %) manjše tveganje glede časa do prve hospitalizacije zaradi srčnega popuščanja (13,9 % v primerjavi z 18,5 %).
English: Consideration should be given to reducing the dose of concomitant diuretics.
Slovenian: Razmisliti je treba tudi o zmanjšanju odmerka sočasno uporabljenih diuretikov.
English: The CHMP considered that the elimination of valsartan at steady-state is similar in patients with renal impairment when compared with healthy volunteers and adopted the following wording: “No dosage adjustment is required for patients with a creatinine clearance >10 ml/min.”
Slovenian: CHMP je menil, da je izločanje valsartana v stacionarnem stanju pri bolnikih z okvaro ledvic podobno kot pri zdravih prostovoljcih, zato je sprejel naslednje besedilo: „Prilagoditev odmerka ni potrebna pri bolnikih s kreatininskim očistkom > 10 ml/min.“
English: The combination of captopril and valsartan has shown no additional clinical benefit, instead the risk for adverse events increased compared to treatment with the respective therapies (see sections 4.2 and 5.1).
Slovenian: Uporaba kombinacije kaptoprila in valsartana ni pokazala dodatnih kliničnih koristi, povečalo pa se je tveganje za neželene učinke v primerjavi z uporabo posameznih zdravil (glejte poglavji 4.2 in 5.1).
English: Exposure to valsartan is not correlated with the degree of liver dysfunction, although the presence of liver disease tended to increase the valsartan plasma AUC.
Slovenian: Izpostavljenost valsartanu ni povezana s stopnjo jetrne disfunkcije, čeprav je prisotnost bolezni jeter navadno povečala površino pod plazemsko koncentracijsko krivuljo (AUC) za valsartan.
English: The safety profile of valsartan was consistent with the clinical course of patients treated in the postmyocardial infarction setting.
Slovenian: Varnostne lastnosti valsartana so se ujemale s kliničnim potekom pri bolnikih, ki so jih zdravili v okviru zdravljenja po miokardnem infarktu.
English: AUC and Cmax values of valsartan are almost proportional with increasing dose over the clinical dosing range (40 to 160 mg twice a day).
Slovenian: Vrednosti AUC in Cmax valsartana se povečujejo linearno in so v mejah kliničnega odmerjanja (40 do 160 mg dvakrat na dan) skoraj sorazmerne večanju odmerka.
English: Hypertension Treatment of essential hypertension.
Slovenian: Hipertenzija Zdravljenje esencialne hipertenzije
English: Post-myocardial infarction and/or heart failure
Slovenian: Po miokardnem infarktu in/ali pri srčnem popuščanju
English: Czech Republic NOVARTIS s.r.o.
Slovenian: Češka republika NOVARTIS s.r.o.
English: Heart failure: Treatment starts generally with 40 mg twice daily.
Slovenian: Srčno popuščanje: Zdravljenje običajno začnemo s 40 mg dvakrat na dan.
English: • elevation of liver function values (which can indicate liver damage) including an increase of bilirubin in the blood (which can, in severe cases, trigger yellow skin and eyes)
Slovenian: • zvišane vrednosti jetrnih testov (kar lahko kaže na poškodbo jeter), vključno z zvišano koncentracijo bilirubina v krvi (ki lahko v hudih primerih povzroči porumenelost kože in oči)
English: In severely sodium-depleted and/or volume-depleted patients, such as those receiving high doses of diuretics, symptomatic hypotension may occur in rare cases after initiation of therapy with Diovan.
Slovenian: Pri bolnikih s hudim pomanjkanjem natrija in/ali hipovolemijo, ki prejemajo velike odmerke diuretikov, lahko v redkih primerih po začetku zdravljenja z zdravilom Diovan pride do simptomatske hipotenzije.
English: Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy As with all other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or hypertrophic obstructive cardiomyopathy (HOCM).
Slovenian: Stenoza aortne in mitralne zaklopke, obstruktivna hipertrofična kardiomiopatija Kot pri uporabi drugih vazodilatatorjev je potrebna posebna pozornost pri bolnikih z aortno ali mitralno stenozo ali s hipertrofično obstruktivno kardiomiopatijo (hypertrophic obstructive cardiomyopathyHOCM).
English: Acknowledging the comments from the CHMP and the Rapporteurs and in the absence of any new data regarding triple therapy with valsartan, the MAH proposed to substitute the wording “the triple combination of an ACE inhibitor, a beta blocker and valsartan is not recommended” in chronic heart failure as requested in the relevant sections of the SPC (sections 4.2 and 4.4).
Slovenian: Ob upoštevanju pripomb odbora CHMP in poročevalcev ter zaradi pomanjkanja novih podatkov v zvezi s trojno terapijo, ki vključuje valsartan, je imetnik dovoljenja za promet z zdravilom predlagal zamenjavo besedila „trojna kombinacija zaviralca ACE, beta zaviralca in valsartana ni priporočljiva“ pri kroničnem srčnem popuščanju, kot se to zahteva v zadevnih poglavjih povzetka glavnih značilnosti zdravila (poglavji 4.2 in 4.4).
English: Composite mortality and morbidity risk was significantly reduced by 18.3% (95% CI: 8% to 28%) with valsartan compared with placebo (31.0% vs. 36.3%).
Slovenian: Tveganje glede sestavljene umrljivosti in obolevnosti je bilo z valsartanom značilno manjše za 18,3 % (95 % IZ: 8% do 28%) v primerjavi s placebom (31,0% v primerjavi z 36,3%).
English: Take Diovan at about the same time each day.
Slovenian: Tablete zdravila Diovan vzemite s kozarcem vode Zdravilo Diovan vzemite vsak dan ob približno istem času.
English: In Study 46, the exposure to valsartan was determined in patients with mild and moderate impairment of liver function.
Slovenian: V študiji 46 so ugotavljali izpostavljenost valsartanu pri bolnikih z blago ali zmerno okvaro delovanja jeter.
English: Slovak Republic Novartis s.r.o.
Slovenian: Slovaška Republika Novartis s.r.o.
English: ADRs that occurred in post-myocardial infarction and/or heart failure patients are listed below:
Slovenian: Neželeni učinki, ki so se pojavljali pri bolnikih po miokardnem infarktu in/ali srčnim popuščanjem, so navedeni spodaj:
English: What Diovan looks like and contents of the pack [To be completed nationally]
Slovenian: Izgled zdravila Diovan in vsebina pakiranja [Izpolni država članica]
English: Having assessed the data available, the CHMP considered that the use of valsartan 80 mg as the starting dose, with no dosage adjustment, in patients with reduced renal function (creatinine clearance rate >10 ml/min) is supported by both efficacy and safety data from various studies.
Slovenian: Po proučitvi razpoložljivih podatkov je CHMP menil, da uporabo 80-miligramskega začetnega odmerka valsartana brez prilagoditve odmerka pri bolnikih z zmanjšanim delovanjem ledvic (kreatininski očistek >10 ml/min) podpirajo podatki o učinkovitosti in varnosti iz več študij.
English: In controlled clinical studies in patients with hypertension, the overall incidence of adverse reactions (ADRs) was comparable with placebo and is consistent with the pharmacology of valsartan.
Slovenian: V kontroliranih kliničnih študijah pri bolnikih s hipertenzijo je bila pogostnost vseh neželenih učinkov primerljiva s tisto pri placebu in v skladu s farmakologijo valsartana.
English: In patients receiving an ACE inhibitor without a beta-blocker, all cause mortality was similar (p=NS) in the valsartan (21.8%) and placebo (22.5%) groups.
Slovenian: Pri bolnikih, ki so prejemali zaviralec ACE brez antagonista adrenergičnih receptorjev beta, je bila umrljivost iz vseh vzrokov podobna (p = NS) v skupini z valsartanom (21,8 %) in s placebom (22,5 %).
English: Administration of Diovan to patients with hypertension results in reduction of blood pressure without affecting pulse rate.
Slovenian: Pri bolnikih s hipertenzijo zdravilo Diovan zniža krvni tlak, ne da bi vplivalo na srčno frekvenco.
English: The recommended starting dose of Diovan is 40 mg twice daily.
Slovenian: Priporočen začetni odmerek zdravila Diovan je 40 mg dvakrat na dan.
English: After an initial dose of 20 mg twice daily, valsartan should be titrated to 40 mg, 80 mg, and 160 mg twice daily over the next few weeks.
Slovenian: Po začetnem odmerku 20 mg dvakrat na dan je treba v naslednjih nekaj tednih valsartan titrirati na 40 mg, 80 mg in 160 mg dvakrat na dan.
English: At 24 weeks, UAE was reduced (p<0.001) by 42% (-24.2 µg/min; 95% CI: -40.4 to -19.1) with valsartan and approximately 3% (-1.7 µg/min; 95% CI: -5.6 to 14.9) with amlodipine despite similar rates of blood pressure reduction in both groups.
Slovenian: Po 24 tednih se je izločanje albumina z urinom zmanjšalo (p < 0,001) za 42 % (-24,2 µg/min; 95 % IZ: -40,4 do -19,1) z valsartanom in približno za 3 % (-1,7 µg/min; 95 % IZ:5,6 do 14,9) z amlodipinom kljub podobnemu obsegu zmanjšanja krvnega tlaka pri obeh skupinah.
English: The CHMP also considered that special precaution would be needed for patients with hepatic impairment and/or cholestasis, as the majority of valsartan is eliminated, mainly as unchanged drug in the bile, by hepatic clearance.
Slovenian: CHMP je prav tako menil, da so pri bolnikih z okvaro jeter in/ali holestazo potrebni posebni previdnostni ukrepi, saj se večina valsartana izloči v obliki nespremenjenega zdravila preko žolča z jetrnim očistkom.
English: • decrease of level of haemoglobin and decrease of the percentage of red blood cells in the blood (which can, in severe cases, lead to anaemia)
Slovenian: • zmanjšana koncentracija hemoglobina in zmanjšan odstotek rdečih krvnih celic v krvi (ki lahko v redkih primerih povzroči anemijo)
English: The CHMP considered the VALIANT study which demonstrated that valsartan given as monotherapy is at least as effective as captopril given as monotherapy in the reduction of total mortality after an acute myocardial infarction.
Slovenian: CHMP je upošteval študijo VALIANT, ki je pokazala, da je monoterapija z valsartanom pri zmanjševanju skupne umrljivosti po akutnem miokardnem infarktu vsaj tako učinkovita kakor monoterapija s kaptoprilom.
English: Regarding renal impairment, the use of valsartan 80 mg as the starting dose, with no dosage adjustment, in patients with reduced renal function (creatinine clearance rate >10 ml/min) is supported by both efficacy and safety data from Study 27 and by pharmacokinetic data from Study 12.
Slovenian: Pri okvari ledvic je 80-miligramski začetni odmerek valsartana brez prilagoditve odmerka pri bolnikih z zmanjšanim delovanjem ledvic (kreatininski očistek > 10 ml/min) podprt s podatki o učinkovitosti in varnosti iz študije 27 in farmakokinetičnimi podatki iz študije 12.
English: the CHMP has recommended the amendment of the Marketing Authorisation(s) for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Diovan and associated names (see Annex I).
Slovenian: je CHMP priporočil spremembo dovoljenj za promet z zdravilom Diovan in z njim povezanih imen (glejte Dodatek I), katerega povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo so navedeni v Dodatku III.
English: Your doctor will increase the dose gradually over several weeks to a maximum of 160 mg twice daily.
Slovenian: Zdravnik bo odmerek v obdobju več tednov postopoma zviševal do največ 160 mg dvakrat na dan.
English: He may also combine Diovan with an additional medicine (e.g. a diuretic).
Slovenian: Zdravilo Diovan lahko doda tudi druga zdravila (npr. diuretike).
English: Regarding the indication in hypertension, the CHMP considered that valsartan is an established therapy for hypertension and there is no substantial discrepancy between the national SPCs.
Slovenian: Glede indikacije, ki se nanaša na hipertenzijo, je CHMP menil, da je valsartan ustaljena terapija za hipertenzijo ter da v zvezi s tem ni pomembnejših razlik med nacionalnimi povzetki glavnih značilnosti zdravila.
English: Regarding hepatic impairment, the CHMP noted that the majority of valsartan is eliminated, mainly as unchanged drug in the bile, through hepatic clearance.
Slovenian: Glede okvare jeter je CHMP izpostavil, da se večina valsartana izloči večinoma v obliki nespremenjenega zdravila preko žolča z jetrnim očistkom.
English: After a recent heart attack: After a heart attack the treatment is generally started as early as after 12 hours, usually at a low dose of 20 mg twice daily.
Slovenian: Po nedavnem srčnem napadu: Po srčnem napadu zdravljenje večinoma začnemo že 12 ur po napadu z nizkimi odmerki 20 mg dvakrat na dan. Odmerek 20 mg dobite tako, da razpolovite 40-miligramsko tableto.
English: -Severe hepatic impairment, biliary cirrhosis and cholestasis.
Slovenian: -Huda okvara jeter, biliarna ciroza in holestaza.
English: The VALsartan In Acute myocardial iNfarcTion trial (VALIANT) was a randomised, controlled, multinational, double-blind study in 14,703 patients with acute myocardial infarction and signs, symptoms or radiological evidence of congestive heart failure and/or evidence of left ventricular systolic dysfunction (manifested as an ejection fraction ≤40% by radionuclide ventriculography or ≤35% by echocardiography or ventricular contrast angiography).
Slovenian: VALIANT (VALsartan In Acute myocardial iNfarcTion) je bila randomizirana, kontrolirana, multinacionalna, dvojno slepa študija, v kateri je sodelovalo 14.703 bolnikov z akutnim miokardnim infarktom, ki so imeli znake, simptome ali radiološke dokaze kongestivnega srčnega popuščanja in/ali znake sistolične disfunkcije levega prekata (kar se kaže kot iztisna frakcija ≤ 40 % pri rentgenski ventrikulografiji ali ≤ 35 % pri ehokardiografiji ali kontrastni angiografiji prekata).
English: • if you are being treated after a heart attack, a combination with ACE inhibitors (a medication to treat heart attack) is not recommended.
Slovenian: • Če se zdravite po srčnem napadu, ni priporočena uporaba kombinacije z zaviralci ACE (zdravili za zdravljenje srčnega napada).
English: In patients with a creatinine clearance <10 ml/min and patients undergoing dialysis no data are available, therefore valsartan should be used with caution in these patients.
Slovenian: Za bolnike s kreatininskim očistkom < 10 ml/min in bolnike, ki so na dializi, ni razpoložljivih podatkov, zato se mora valsartan pri takih bolnikih uporabljati s previdnostjo.
English: In section 4.2 there are also differences in SPC across Member States in relation to the dosage recommendation in patients with renal and hepatic impairment.
Slovenian: Povzetki glavnih značilnosti zdravila držav članic se razlikujejo tudi v poglavju 4.2, in sicer v zvezi s priporočljivim odmerkom za bolnike z okvaro ledvic in jeter.
English: Diovan was included in the list of products for Summary of Products Characteristics (SPC) harmonization, drawn up by the CMD(h), in accordance with Article 30(2) of Directive 2001/83/EC, as amended, as the above-mentioned medicinal product does not have the same SPC across all EU Member States, Iceland and Norway.
Slovenian: Ker zdravilo Diovan nima enakega povzetka glavnih značilnosti zdravila v vseh državah članicah EU, na Islandiji in Norveškem, je bilo vključeno na seznam zdravil, za katera je treba uskladiti povzetke glavnih značilnosti zdravila, ki ga je sestavil CMD(h) v skladu s členom 30(2) Direktive 2001/83/ES, kakor je bila spremenjena.
English: Valsartan was as effective as captopril in reducing all-cause mortality after myocardial infarction.
Slovenian: Valsartan je bil pri zmanjševanju umrljivosti iz vseh vzrokov po miokardnem infarktu enako učinkovit kot kaptopril.
English: Discontinuations due to various types of renal dysfunction occurred in 1.1% of valsartan-treated patients, 1.3% in valsartan+captopril patients, and 0.8% of captopril patients.
Slovenian: Do prekinitve zdravljenja zaradi različnih vrst ledvične disfunkcije je prišlo pri 1,1 % bolnikov, ki so se zdravili z valsartanom, pri 1,3 % bolnikov, ki so se zdravili s kombinacijo valsartana in kaptoprila, in pri 0,8 % bolnikov, ki so se zdravili s kaptoprilom.
English: In the overall Val-HeFT population, valsartan treated patients showed significant improvement in NYHA class, and heart failure signs and symptoms, including dyspnoea, fatigue, oedema and rales compared to placebo.
Slovenian: V celotni populaciji študije Val-HeFT se je pri bolnikih, zdravljenih z valsartanom, pokazalo značilno izboljšanje po razvrstitvi NYHA in v znakih ter simptomih srčnega popuščanja, vključno z dispnejo, utrujenostjo, edemom in s piskanjem pri dihanju v primerjavi s placebom.
English: The combination with ACE inhibitors is not recommended (see sections 4.4 and 5.1).
Slovenian: Kombinacija z zaviralci ACE ni priporočljiva (glejte poglavji 4.4 in 5.1).
English: “Treatment of clinically stable patients with symptomatic heart failure or asymptomatic left ventricular systolic dysfunction after a recent (12 hours - 10 days) myocardial infarction”
Slovenian: „Zdravljenje klinično stabilnih bolnikov s simptomatskim srčnim popuščanjem ali asimptomatsko sistolično disfunkcijo levega prekata po nedavnem (12 ur-10 dni) miokardnem infarktu.“
English: • [Storage conditions statements - To be completed nationally]
Slovenian: • [Pogoji shranjevanja - izpolni država članica]